Active Juvenile Psoriatic Arthritis clinical trials

Explore recruiting active juvenile psoriatic arthritis clinical trials.

Recruiting active juvenile psoriatic arthritis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Active Juvenile Psoriatic Arthritis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD)

France, Portugal, Belgium, Lithuania, Germany, Netherlands +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open-label, randomized, assessor-blinded, efficacy, safety, tolerability, and pharmacokinetics study of subcutaneous risankizumab with an adalimumab reference arm in children with active juvenile psoriatic arthritis

Poland, Spain, France, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)

France, Poland, Netherlands, Spain, Germany, Denmark +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents from 5 to less than 18 Years of Age with Active Juvenile Psoriatic Arthritis

Italy, Czechia, Bulgaria, Romania, Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Active Juvenile Psoriatic Arthritis trials by city

Active Juvenile Psoriatic Arthritis in Toronto Active Juvenile Psoriatic Arthritis in Vancouver Active Juvenile Psoriatic Arthritis in Montreal Active Juvenile Psoriatic Arthritis in Calgary Active Juvenile Psoriatic Arthritis in Edmonton Active Juvenile Psoriatic Arthritis in Ottawa Active Juvenile Psoriatic Arthritis in Winnipeg Active Juvenile Psoriatic Arthritis in Quebec City Active Juvenile Psoriatic Arthritis in Hamilton Active Juvenile Psoriatic Arthritis in Kitchener Active Juvenile Psoriatic Arthritis in London Active Juvenile Psoriatic Arthritis in Halifax Active Juvenile Psoriatic Arthritis in New York Active Juvenile Psoriatic Arthritis in Los Angeles Active Juvenile Psoriatic Arthritis in Chicago Active Juvenile Psoriatic Arthritis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease